There is a lot happening in Cambridge, England. The university might have passed its 800th anniversary earlier in this century but the basics of its operating model to bring the smartest people in the world together to solve its hardest challenges remains intact.

Tim Haines, managing partner of Abingworth, a biotech venture-capital firm, in the latest Economist said we were in “the golden age of diagnostics”.

Bond issuance by investment-grade-rated American companies jumped to a record $1.7trn in 2020, up from $1.1trn in 2019, according to S&P Global Market Intelligence, a research outfit.

The gamification of life continues, just updated for the modern world it seems.

Medical devices and diagnostics has often been regarded as the underloved part of the healthcare venture market compared with biotech and pharma, with relatively few deals and limited exit options.

Back in the day, money laundering used to be a relatively simple affair. Take a bag of cash to a casino, “lose” 10% to 20% and walk away with the bulk in cleaned money.

The May issue of GCV and special report on AI are available to download now.

The covid-19 pandemic has been regarded as the long-awaited start of the “biological century”.

The merger of corporate venture-backed Gojek and Tokopedia, Indonesia’s two biggest startups, has focused attention on the global success story happening in southeast Asia.

Azimut, an Italy-based asset manager managing about $70bn, last week acquired 30% of P101, a local venture capital (VC) firm with €200m ($240m) of assets under management.